ClearPoint Neuro (CLPT) announced the acquisition of San Diego based, Irras Holdings. Its cornerstone product is the IRRAflow system, an FDA-cleared and CE-marked platform which integrates continuous irrigation, aspiration, and real-time intracranial pressure monitoring. The deal brings more than 50 active customers to the ClearPoint Neuro installed base and 10 additional patent families. Based on management’s current forecasts for ClearPoint Neuro’s business and its assessment of the Irras business, the total 2026 combined revenue for the two companies is expected to be in the range of $54M to $60M.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- Largest borrow rate increases among liquid names
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Why Is ClearPoint Neuro Stock (CLPT) Up Today?
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- Unusually active option classes on open September 24th